



MindMed

PRESS RELEASE

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Mind Medicine (MindMed) Inc.
(NASDAQ: MNMD, NEO: MMED, DE:
MMQ; the "Company"), a leading
biotech company developing

psychedelic-inspired therapies, is pleased to announce that Dr. Matt Liechti presented data from several ongoing studies at the **INSIGHT Conference** in Berlin, Germany. These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.

Novel findings presented by the UHB Liechti Lab include:

Comparative Effects of LSD and Psilocybin: The perceptual effects of a dose of 100 mcg LSD were found to be equivalent to a dose of 20 mg psilocybin in healthy volunteers. This is the first

direct clinical evidence demonstrating the equivalence of psilocybin and LSD on acute psychedelic effects.

Psychedelics & SSRIs: Psilocybin was found to be safe to administer together with an antidepressant. Daily pretreatment with escitalopram for two weeks prior to psilocybin administration, reduced anxiety and blood pressure increases associated with psilocybin but did not reduce the acute psychedelic experience in healthy volunteers.

“While both LSD and psilocybin have a long history in psychiatric research, psilocybin is being studied in a majority of ongoing clinical trials of psychedelics,” said Dr. Liechti. “It is important for us to understand the

acute effect characteristics of different psychedelics, and to understand how these substances interact with other treatments like antidepressants. We look forward to fully analyzing the exciting data produced by these studies and publishing our findings later this year."

MindMed CEO Robert Barrow said, "Investors and researchers alike are eager to understand the similarities between psilocybin and LSD. Learning how these substances compare and interact with other drugs helps us ensure that our treatment programs

are as effective and efficient as possible."

MindMed Executive President, Dr. Miri Halperin Wernli said, "The psychedelic experience can be conceptualized as the facilitated transforming encounter between one's fears and longings with the universe and its network of living processes. This work with Professor Liechti, indicating for example that genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD, is an illustration that biological and psychological transformation

processes may be deeply interwoven
When LSD is the chosen key to open
an opportunity for psycho-
transformation and growth, individual
parameters such as one's own
metabolization and bio-transformation
rhythm have to be carefully understood
and taken into consideration in order
to allow the transformative effect to
happen in the most powerful and safe
manner."

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the

next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature.

Forward-looking information is not based on historical facts, but rather current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release

include, but are not limited to, statements regarding the analysis of the data produced by studies relating to LSD and psilocybin and the timing of publication of related findings. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous

risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic

inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings "Risk Factors" in the Company's filings with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from


those anticipated in such information.

Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

LINK TO THE ORIGINAL ARTICLE:




Browse more articles





PRESS RELEASE

MindMed Announces Participation at Upcoming Investor Conferences



VIDEO

H.C. Wainwright 23rd Annual Global Investment Conference



MindMed

PRESS RELEASE

MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference



[BACK TO ALL NEWS](#)

MindMed

MindMed Headquarters
One World Trade Center
Suite 8500
New York, NY 10007, USA

NEO: **MMED**
NASDAQ:
MNMD



Our Medicines

Experiential Therapies

Our Focus

Anxiety

Psychedelic Inspired

Next-Gen R&D

Addiction

Adult ADHD

Investors

Press Releases

Downloads

Corp. Governance

Financials

About Us

News / Blog

Our Team

Partnerships

Merch

Careers

Contact Us

Get MindMed Updates:

you@yours.com



